Movement Alert|Legend Biotech Falls 5.02% in Regular Trading, Analysts Cut Price Targets After Quarterly Results

Market Focus11-13

On November 13, Legend Biotech fell 5.02% in Regular Trading, trading at $18.56 per share, with turnover of $66.8695 million.

The clearest catalyst was post-earnings analyst target-price cuts after the company reported third-quarter results that showed profit improvement but slightly missed revenue expectations.

Legend Biotech reported third-quarter net profit of $51.7 million, versus a loss a year earlier, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue was $359.5 million, below the roughly $361.5 million market expectation. After the release, RBC cut its target price to $50 from $56 while maintaining Outperform; Morgan Stanley lowered its target to $43; and Oppenheimer reduced its target to $25. RBC still said Carvykti is positioned to sustain growth into 2027, but the immediate market reaction reflected the revenue shortfall and lowered valuation assumptions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment